News

HDA UK Media And Political Bulletin – 2 February 2018

Media and Political Bulletin

2 February 2018

Media Summary

EMA admits temporary Amsterdam home ‘not optimal solution’

The Pharmaceutical Journal, 1 February 2018

 

The Pharmaceutical Journal reports that initial plans for a temporary building to house the European Medicines Agency (EMA) after it moves to Amsterdam have been shelved after it was concluded that the intended accommodation was not “fully fit for purpose”, EMA executive director, Guido Rasi, has said.

Rasi said Dutch authorities had been asked to find an alternative to the EMA’s proposed temporary home and while a decision on new premises had taken “longer than expected” new short-term accommodation had now been found.

But he admitted that the temporary premises were still “not an optimal solution” as they would only provide half the space currently available in the EMA’s London location. As a result, external facilities will need to be used for anything other than “core scientific meetings”.

 

Parliamentary Coverage

Department of Health and Social Care – European Medicines Agency, 1 February 2018

Virendra Sharma: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the UK’s withdrawal from the European Medicines Agency on the UK health sector.

Jackie Doyle-Price: We recognise the important role that the European Medicines Agency plays in the protection of human and animal health.

In negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the United Kingdom and the EU.

The UK is fully committed to continuing the close working relationship with our European partners. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data. As the Prime Minister has stated, we want deep, broad and dynamic co-operation and in this context, the UK would like to find a way to continue to collaborate with the EU, in the interests of public health and safety.

Full Coverage

EMA admits temporary Amsterdam home ‘not optimal solution’

The Pharmaceutical Journal, 1 February 2018

 

Initial plans for a temporary building to house the European Medicines Agency (EMA) after it moves to Amsterdam have been shelved after it was concluded that the intended accommodation was not “fully fit for purpose”, EMA executive director, Guido Rasi, has said.

Rasi said Dutch authorities had been asked to find an alternative to the EMA’s proposed temporary home and while a decision on new premises had taken “longer than expected” new short-term accommodation had now been found.

But he admitted that the temporary premises were still “not an optimal solution” as they would only provide half the space currently available in the EMA’s London location. As a result, external facilities will need to be used for anything other than “core scientific meetings”.

“We are working against extremely tight deadlines,” said Rasi.

“On 1 January 2019 we need a fully operational building in order to move our staff gradually from London to Amsterdam before 30 March 2019, when the UK withdraws from the EU. That means that even if these temporary premises are not ideal, they are the best option under the current time restrictions.”

In his statement, Rasi explained that the double transfer will force the EMA to invest more resources and means it will take the organisation longer to get back to “normal operations”.

However he assured that the EMA would do its utmost to make the double move work.

The planned move to Amsterdam from the EMA’s current Canary Wharf headquarters had always included temporary accommodation while the organisation’s new permanent home, the Vivaldi Building, was completed.

An internal survey carried out in 2017 showed that 81% of EMA staff would be willing to move to Amsterdam. Among the 19 EMA candidate cities Amsterdam scored highest in terms of staff retention.

However, a spokesperson for the EMA said it was still too early to determine exactly how many staff would relocate.

“Staff are encouraged to reflect on whether they would relocate with the Agency and one-on-one meetings will be held to get a clearer picture of people’s plans by the end of February,” they said.

HDA UK Media And Political Bulletin – 2 February 2018

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?